Transcode Therapeutics Stock Performance
| RNAZ Stock | USD 0.34 0.04 9.71% |
Transcode Therapeutics holds a performance score of 6 on a scale of zero to a hundred. The entity has a beta of -1.8, which indicates a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Transcode Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, Transcode Therapeutics is expected to outperform it. Use Transcode Therapeutics total risk alpha, as well as the relationship between the downside variance and daily balance of power , to analyze future returns on Transcode Therapeutics.
Risk-Adjusted Performance
6 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Transcode Therapeutics are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Transcode Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:40 | Last Split Date 2024-01-16 |
1 | TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidates Preclinical Efficacy Against Metast... | 09/10/2024 |
2 | Acquisition by Manting Erik of 9500 shares of Transcode Therapeutics at 0.2985 subject to Rule 16b-3 | 10/04/2024 |
3 | Acquisition by Robert Dudley of 6607 shares of Transcode Therapeutics at 2.5498 subject to Rule 16b-3 | 10/08/2024 |
4 | TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Coh... | 10/23/2024 |
5 | TransCode Therapeutics Inc Quarterly 10-Q Report - Quartzy | 11/15/2024 |
6 | TransCode Therapeutics advances with stockholder approvals | 11/25/2024 |
| Begin Period Cash Flow | 5 M |
Transcode |
Transcode Therapeutics Relative Risk vs. Return Landscape
If you would invest 26.00 in Transcode Therapeutics on August 30, 2024 and sell it today you would earn a total of 8.31 from holding Transcode Therapeutics or generate 31.96% return on investment over 90 days. Transcode Therapeutics is currently generating 1.0945% in daily expected returns and assumes 12.3596% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Transcode, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Transcode Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Transcode Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Transcode Therapeutics, and traders can use it to determine the average amount a Transcode Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0886
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | RNAZ | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 12.36 actual daily | 96 96% of assets are less volatile |
Expected Return
| 1.09 actual daily | 21 79% of assets have higher returns |
Risk-Adjusted Return
| 0.09 actual daily | 6 94% of assets perform better |
Based on monthly moving average Transcode Therapeutics is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Transcode Therapeutics by adding it to a well-diversified portfolio.
Transcode Therapeutics Fundamentals Growth
Transcode Stock prices reflect investors' perceptions of the future prospects and financial health of Transcode Therapeutics, and Transcode Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Transcode Stock performance.
| Return On Equity | -10.49 | ||||
| Return On Asset | -2.08 | ||||
| Current Valuation | 4.79 M | ||||
| Shares Outstanding | 17.27 M | ||||
| Price To Book | 3.94 X | ||||
| EBITDA | (17.97 M) | ||||
| Net Income | (18.55 M) | ||||
| Cash And Equivalents | 13.45 M | ||||
| Cash Per Share | 1.04 X | ||||
| Total Debt | 450.57 K | ||||
| Current Ratio | 8.06 X | ||||
| Book Value Per Share | 2.62 X | ||||
| Cash Flow From Operations | (18.07 M) | ||||
| Earnings Per Share | 168.84 X | ||||
| Market Capitalization | 6.51 M | ||||
| Total Asset | 5.17 M | ||||
| Retained Earnings | (46.42 M) | ||||
| Working Capital | 964.85 K | ||||
About Transcode Therapeutics Performance
Evaluating Transcode Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Transcode Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Transcode Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 1.8 K | 1.6 K | |
| Return On Tangible Assets | (3.59) | (3.77) | |
| Return On Capital Employed | (11.56) | (10.99) | |
| Return On Assets | (3.59) | (3.77) | |
| Return On Equity | (11.30) | (10.74) |
Things to note about Transcode Therapeutics performance evaluation
Checking the ongoing alerts about Transcode Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Transcode Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Transcode Therapeutics is way too risky over 90 days horizon | |
| Transcode Therapeutics has some characteristics of a very speculative penny stock | |
| Transcode Therapeutics appears to be risky and price may revert if volatility continues | |
| Transcode Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (18.55 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Transcode Therapeutics currently holds about 13.45 M in cash with (18.07 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.04, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Transcode Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from investing.com: TransCode Therapeutics advances with stockholder approvals |
- Analyzing Transcode Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Transcode Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Transcode Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Transcode Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Transcode Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Transcode Therapeutics' stock. These opinions can provide insight into Transcode Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Transcode Stock Analysis
When running Transcode Therapeutics' price analysis, check to measure Transcode Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transcode Therapeutics is operating at the current time. Most of Transcode Therapeutics' value examination focuses on studying past and present price action to predict the probability of Transcode Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transcode Therapeutics' price. Additionally, you may evaluate how the addition of Transcode Therapeutics to your portfolios can decrease your overall portfolio volatility.